The assessment of the safety, effectiveness, and manufacturing quality of a new animal drug is a continuing process that takes place throughout the development and marketing of that drug. CVM uses risk-based approaches to protect consumers and animals from drugs that are not safe, effective, or quality manufactured.

Each FDA-TRACK program area collects, analyzes, and reports its performance measures and results. Explore the progress CVM is making towards its Post-market Drug Safety, Effectiveness, and Quality strategic initiative below:

I. Percentage of Animal Drug Export Certificates issued within 20 days of receipt

II. Percentage of Animal Drug Health Hazard Evaluations processed by the due date

III. Percentage of Tissue Residue and Unapproved Drug Warning Letter Recommendation Packages reviewed within 25 days of receipt

---

I. Percentage of Animal Drug Export Certificates issued within 20 days of receipt

Return to top

---

II. Percentage of Animal Drug Health Hazard Evaluations processed by the due date

Return to top

---

III. Percentage of Tissue Residue and Unapproved Drug Warning Letter Recommendation Packages reviewed within 25 days of receipt

Return to top

---

Note:  The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time.